TBPH vs. DVAX, ARQT, GLPG, INDV, AKRO, DYN, EVO, GPCR, TVTX, and XNCR
Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Dynavax Technologies (DVAX), Arcutis Biotherapeutics (ARQT), Galapagos (GLPG), Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Evotec (EVO), Structure Therapeutics (GPCR), Travere Therapeutics (TVTX), and Xencor (XNCR). These companies are all part of the "pharmaceutical preparations" industry.
Theravance Biopharma vs.
Dynavax Technologies (NASDAQ:DVAX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership.
Dynavax Technologies has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.
Dynavax Technologies currently has a consensus price target of $23.00, indicating a potential upside of 84.74%. Theravance Biopharma has a consensus price target of $13.75, indicating a potential upside of 60.26%. Given Dynavax Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Dynavax Technologies is more favorable than Theravance Biopharma.
Dynavax Technologies has a net margin of 7.85% compared to Theravance Biopharma's net margin of -78.18%. Dynavax Technologies' return on equity of 3.19% beat Theravance Biopharma's return on equity.
In the previous week, Dynavax Technologies had 19 more articles in the media than Theravance Biopharma. MarketBeat recorded 25 mentions for Dynavax Technologies and 6 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.08 beat Dynavax Technologies' score of 0.82 indicating that Theravance Biopharma is being referred to more favorably in the news media.
97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by insiders. Comparatively, 6.9% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Dynavax Technologies received 132 more outperform votes than Theravance Biopharma when rated by MarketBeat users. Likewise, 65.97% of users gave Dynavax Technologies an outperform vote while only 62.80% of users gave Theravance Biopharma an outperform vote.
Dynavax Technologies has higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Dynavax Technologies beats Theravance Biopharma on 12 of the 16 factors compared between the two stocks.
Get Theravance Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theravance Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:TBPH) was last updated on 1/21/2025 by MarketBeat.com Staff
Free TBPH Stock Alerts